About Natera
Natera is a publicly listed company based in Redwood City (United States) founded in 2004. Natera has raised $152.1 million across 13 funding rounds from investors including Lightspeed Venture Partners, Franklin Templeton and HHS. The company has 4,430 employees. Natera has completed 1 acquisition, including Foresight Diagnostics. Its website natera.com draws about 1.1 million monthly visits. Natera offers products and services including Signatera, Panorama, Prospera, Horizon, and Renasight. Its focus areas include Life Sciences, Clinical Genomics, Sequencing Based and Genetic Testing. Its legal entity is Natera, Inc. Its competitors include Guardant Health, Foundation Medicine and ArcherDX; 3 of its 3 listed competitors have raised funding.
Company details
Developer of cell-free DNA testing for oncology, womens health, and organ health. The test provided by the company inlcude Signatera a residual disease test (MRD), Altera tumor genomic profile, Empower Hereditary cancer test, Prospera Kidney transplant assessment, Panorama Noninvasive prenatal testing (NIPT), Anora Miscarriage Test, and more.
- Headquarters Redwood City, United States
- Employees 4,430
- Stage Public
- SectorsHealthcare
- Website category Health · Womens Health
- Website natera.com
- Social LinkedIn X Facebook Instagram
- Legal Name Natera, Inc.
- Annual Revenue$2.31 B (USD)35.9as on Dec 31, 2025
- Net Profit-$208.16 M (USD)-9.31as on Dec 31, 2025
- EBITDA-$262.53 M (USD)-37.21as on Dec 31, 2025
- Total Equity Funding$152.1M (USD)
in 13 rounds
- Latest Funding Round$287.5M (USD), Post-IPO
Apr 2020
- InvestorsLightspeed Venture Partners
& 14 more
- Employee Count4,430
- Investments & Acquisitions
Products & Services of Natera
Natera offers a comprehensive portfolio of products and services, including Signatera, Panorama, Prospera, Horizon, and Renasight.
Detects residual disease in cancer patients through DNA analysis
Screens for genetic conditions in prenatal testing
Assesses transplant organ health via DNA monitoring
Provides carrier screening for genetic disorders
Evaluates kidney gene panels for health risks
Funding Insights of Natera
Natera has successfully raised a total of $152.1M across 13 strategic funding rounds. The most recent funding activity was a Post-IPO round of $287.5 million completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $152.1M
- Total Rounds 13
- Last Round Post-IPO — $287.5M
- First Round $1.49M
(Aug 2006)
- Investors Count 15
Latest 10 of 13 funding rounds of Natera with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2020 | $287.5M | Post-IPO | – | – | – |
| Apr 2015 | $55.5M | Series F | – | – | |
| May 2013 | $54.6M | Series E | – | – | |
| Jan 2012 | $20M | Series D | – | – | |
| Nov 2010 | $12M | Series C | – | – | |
| Aug 2010 | $1.8M | Grant | – | – | |
| Aug 2010 | $1.8M | Grant | – | – | |
| Feb 2009 | $1.8M | Grant | – | – | |
| Feb 2009 | $1.8M | Grant | – | – | |
| Jan 2009 | $6M | Series B | – | – |
15 investors in total: 15 institutional.
Investors in Natera
Natera has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Lightspeed Venture Partners, Franklin Templeton and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com | |||
| healthcorpartners.com | ||||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Venture capital investing in innovative companies across global sectors is undertaken by Lightspeed Venture Partners. | 1997 | lsvp.com | Menlo Park, United States | |
Sequoia Capital is engaged in venture capital investments. | 1972 | sequoiacap.com | ||
Seed and early-stage venture capital firm investing in digital solutions for healthcare and energy industries. | claremontcreek.com | |||
Venture capital investments in technology and defense sectors. | foundersfund.com | |||
Life-Sciences focused early & growth stage VC firm investing in the US & Europe | alafi.com | San Francisco, United States | ||
Venture capital is provided to expansion-stage software and tech firms. | harmonyvp.com | New York, United States | ||
Diversified investment management services are offered globally by the firm. | 1947 | franklintempleton.com | New York, United States |
Investor details for Natera
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Natera
703 people are tracked at Natera (254 in leadership, 1 in board & advisors, 448 in team); the tracked headcount is 4,430.
| Name | Role | Group |
|---|---|---|
Jeffrey Dungan | Medical Director, Women's Health | Leadership |
Ryan Swenerton | Senior Director, R&d | Leadership |
Ersel Kullolli | Director Of Product Management | Leadership |
Jeffrey Weitzel | Consulting Medical Director | Leadership |
Priyanka Arya | Laboratory Director | Leadership |
Rishi Kacker | CTO | Leadership |
Steve Chapman | CEO | Leadership |
Patrick Miller | Vice President Of Marketing, Strategy, & BD - Organ Health | Leadership |
Gabrielle Heilek | Vice President Research And Development, Oncology | Leadership |
Kellie H. | Director Of Patient Experience | Leadership |
Mark Calhoun | Associate Director - Gu, Breast, Heme Oncology Msls | Leadership |
Steve le | Director Of Oncology Strategic Accounts | Leadership |
Allison Mirza | Director Of Marketing, Organ Health Renasight | Leadership |
Ulka Shrikhande | Director, Early Cancer Detection Lead | Leadership |
Justin Alter Mba | Director, GYN Oncology Sales | Leadership |
Keith Hanigan | Vice President Oncology Commercial Marketing | Leadership |
Lulu Liu | Head Of Oncology Marketing Development | Leadership |
Bernie Tobin | General Manager, Organ Health | Leadership |
Johannes Reiter | Director, Bioinformatics | Leadership |
Zachary Demko | * Senior Director Of Scientific Communications And Clinical Research | Leadership |
683 more people are available in the full profile.
Complete people profiles for Natera
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Natera
Natera is a publicly listed company on the NASDAQ with ticker symbol NTRA in USA, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date02 Jul 2015
- Listed onNASDAQ: NTRA
- Listed entityNatera, Inc.
- Exchange sectorHealth services
- ISINUS6323071042
- Share price$395.65 (-0.53% on the day) · 2026-10-13
- Market capitalisation$57.03B
- EPS (diluted, trailing year)$-1.37
- Volume (last session)1,131,579
Financials of Natera
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $2.31B | -$208.2M | -$262.5M |
| 2024 | $1.70B | -$190.4M | -$191.3M |
| 2023 | $1.08B | -$434.8M | -$404.9M |
| 2022 | $820.2M | -$547.8M | -$501.3M |
| 2021 | $625.5M | -$471.7M | -$421.3M |
Detailed financial statements for Natera
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Natera
Natera has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Foresight Diagnostics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Minimally invasive liquid biopsy tests for cancer detection are developed. | foresight-dx.com | Aurora, United States | 2020 | Dec 2025 | •••• |
Complete acquisition details for Natera
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Natera
5 dated milestones of Natera across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Natera is founded.
- Funding First funding round of $1.5M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $287.5M.
- Acquisition Acquires Foresight Diagnostics.
Competitors of Natera
Natera has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, Foundation Medicine and ArcherDX.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. | |
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. |
Detailed competitors of Natera
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Natera
The website of Natera (natera.com) receives about 1.1M visits a month and ranks #40,970 among all websites worldwide, #1,027 in Womens Health.
- Monthly visits1.1M
▲ 6.2% vs previous month
- Unique visitors300.9K
per month
- Global rank#40,970
among all websites
- Category rank#1,027
Health · Womens Health
- Bounce rate33%
- Pages per visit6.4
- Average visit5 min 10 sec
- DevicesDesktop 40% · Mobile 60%
Websites whose visitors overlap most with Natera. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
panoramatest.com | panoramatest.com | 100% | – | ||
| ariosadx.com | 91% | View details | |||
| prenatalgeneticscenter.com | 79% | View details | |||
| nccn.org | 74% | #61,038 | View details | ||
easy-dna.com | easy-dna.com | 71% | #1,752,189 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Natera
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Natera (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Natera
Complete news archive for Natera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Natera
Natera was founded in 2004 and raised its 1st funding round 2 years after it was founded.
Natera is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
Natera is a funded company, having raised a total of $152.1M across 13 funding rounds to date. The company's 1st funding round was a Series B of $6M, raised on Aug 2006.
Natera has 4,430 employees.
Annual revenue of Natera is $2.31B as on Dec 31, 2025.
Developer of cell-free DNA testing for oncology, womens health, and organ health. The test provided by the company inlcude Signatera a residual disease test (MRD), Altera tumor genomic profile, Empower Hereditary cancer test, Prospera Kidney transplant assessment, Panorama Noninvasive prenatal testing (NIPT), Anora Miscarriage Test, and more.
Natera's top competitors include Guardant Health, Foundation Medicine and ArcherDX.
Natera offers Signatera, Panorama, Prospera, Horizon, and Renasight.
Yes, Natera is publicly traded on NASDAQ under the ticker symbol NTRA.
Natera has made 1 acquisition, including Foresight Diagnostics.
Natera has 15 investors. Key investors include Lightspeed Venture Partners, Franklin Templeton, HHS, Orbimed, and RA Capital.
Natera operates through Natera, Inc..